Drug Master File for Prostate Imaging Product Filed with the FDA
MELBOURNE, Australia and INDIANAPOLIS, March 26, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) ("Telix Group", "Company"), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), has today announced the submission of a Drug Master File (DMF) for a sterile kit used in the preparation of 68Ga-PSMA-11 (PSMA Kit), to the US Food and Drug Administration (FDA DMF ID: 032631).
Dr. Bernard Lambert, President of Telix USA noted, "The filing of this DMF marks an important step toward offering a commercial PSMA prostate imaging solution for the US market, and we are the first to have achieved this accomplishment in collaboration with our partner, ANMI. There is considerable demand for effective prostate imaging in the United States and we already have several leading cancer hospitals preparing to use the PSMA Kit. We'd also like to acknowledge the excellent work of our colleagues at NukeMed and the team at Indiana University, who worked tirelessly over the past six months to complete the validation work."
The PSMA Kit has been validated for use with all major vendors of 68Ga generators, including Eckert & Ziegler1, ITM2 and IRE ELiT3. The PSMA Kit is expected to be commercially available by mid-2018, subject to FDA review of the manufacturing package. The DMF is held by Kyzeo Imaging LLC (Kyzeo), a joint-venture company between Telix Pharmaceuticals (US) Inc. and ANMI SA.
About the US Prostate Cancer Imaging Market
Prostate cancer has emerged as a major cancer killer in the United States, with approximately 160,000 new cases annually and three million men living with prostate cancer.4 There remains a significant unmet need to better diagnose and stage men with prostate cancer, from initial diagnosis all the way to therapeutic monitoring in patients with late-stage metastatic disease. The prostate imaging market in the US is estimated to be a $500m market opportunity, likely to be dominated by the use of Positron Emission Tomography (PET) and imaging agents targeting prostate-specific membrane antigen (PSMA) in particular.5
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (Telix Group, Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.
About ANMI SA
ANMI SA is a precursor supplier for radiometal labelled radiopharmaceuticals and a global service provider in the nuclear medicine field, located in Liège, Belgium. ANMI has developed innovative solutions to facilitate the scalable synthesis of "theranostic" radiopharmaceuticals and to ease their daily production in hospitals. ANMI's vision is focused on increasing patient access to new high-performance radiopharmaceuticals through streamlined and cost-effective production processes. For more information visit www.anmi.be.
About Kyzeo Imaging, LLC
Kyzeo Imaging, LLC is US-based JV between ANMI and Telix USA (the US operating entity of Telix Group) to commercialize a sterile cold kit for the preparation of 68Ga-PSMA-11 for the imaging of prostate cancer with Positron Emission Tomography (PET). The commercial partnership is structured as a JV to support a profit-sharing arrangement between Telix USA and ANMI, and to support the use of the PSMA Kit in 3rd party clinical trials of novel prostate cancer therapeutics in a commercially arms-length manner from Telix Group. Telix USA is the exclusive distribution partner for the PSMA Kit in the US market.
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.
None of the products described in this release have obtained a marketing authorization from the US Food and Drug Administration.
4 American Cancer Society : https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html
5 Jadvar et al. J Nucl Med February 1, 2018 vol. 59 no. 2 228-229
Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: firstname.lastname@example.org Investor and Media Relations Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: email@example.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Telix Pharmaceuticals Limited via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Raising Internal Awareness About GDPR is Main Challenge, Say Subscription Businesses25.4.2018 20:00 | Pressmeddelande
WARRINGTON, United Kingdom, April 25, 2018 (GLOBE NEWSWIRE) -- With the countdown to the arrival of GDPR reaching the critical stages, more than a third of subscription businesses say that their biggest remaining challenge is raising internal awareness and knowledge about the legislation. GDPR comes into force May 25, with major implications for subscription businesses that collect personal data from B2B or B2C customers located in the EU. MPP Global hosted two recent webinars, focusing on the roles of data processor and data controller, to help businesses understand their responsibilities under the new regulations. Research conducted during these webinars uncovered that the main challenge identified by 34 percent of attendees ahead of GDPR was ensuring that their colleagues were aware of the changes in legislation and the potential implications of a breach. "These findings show that there is still some work to be done around GDPR," said MPP Global CEO and Co-Founder Paul Johnson. "GDP
PowerPlan Named Finalist for 2018 SAP® Pinnacle Award25.4.2018 16:10 | Pressmeddelande
ATLANTA, April 25, 2018 (GLOBE NEWSWIRE) -- PowerPlan is pleased to announce that SAP has recognized it as a finalist for an SAP® Pinnacle Award in the ISV Partner of the Year - Technology Innovation Award category. The annual SAP Pinnacle Awards acknowledge the contributions of leading SAP partners that have excelled in developing and growing their partnership with SAP and helping customers meet their goals. Finalists and winners in 29 categories were chosen based on recommendations from the SAP field, customer feedback and performance indicators. "We're honored to be recognized by SAP. Our distinction as a finalist highlights that the visions of PowerPlan and SAP continue to align," said Brent Burns, COO, PowerPlan. PowerPlan has been an OEM partner for SAP since June 2017. The introduction of the PowerPlan Adapter for SAP S4/HANA gained popularity due to its advanced cloud functionality and user-friendly interface. "Working with SAP has enabled our clients to run simple, yet strateg
Appian Announces 2018 Global and Regional Partners of the Year25.4.2018 15:01 | Pressmeddelande
RESTON, Va., April 25, 2018 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) today announced its 2018 Global and Regional Partners of the Year winners. These strategic partners were selected based on their success in helping companies develop and execute digital transformation initiatives using Appian's low-code platform. Appian's partner ecosystem is consists of organizations that provide world-class solutions and services globally across a variety of industries. Global and Regional Partner of the Year Winners: Global Partner of the Year - KPMG Regional Partner of the Year, Europe - PwC Regional Partner of the Year, APAC - Incessant Regional Partner of the Year (Mid-Market) - Bits In Glass Global Trusted Program: Partner of the Year - Vuram "Our recognition as Appian's Global Partner of the Year for the third consecutive year demonstrates the strength of our combined business and technology leadership," said Jerry Iacouzzi, U.S. leader for digital enablement at KPMG. "Digital transformation i
LeoVegas kommentar på information gällande ändrade förutsättningar på den norska marknaden25.4.2018 14:32 | Pressmeddelande
I LeoVegas finansiella mål om intäkter på minst 600 MEUR år 2020 och minst 100 MEUR i EBITDA år 2020, som presenterades 19 april, har det tagits i beaktning att marknadsförutsättningar kan förändras. Meddelandet igår om förslaget till norska stortinget är ett exempel på ändrade förutsättningar som LeoVegas strategiska planering tagit höjd för. LeoVegas strävar efter att vara ett transparent bolag och väljer därför att ange storleken på den norska marknaden för att ge en ökad förståelse. I mars 2018 stod den norska marknaden för 4,6% av koncernens totala intäkter. Oavsett utgång påverkar utvecklingen i Norge inte LeoVegas finansiella mål. "Ännu finns det inga detaljer kring förslaget men i alla branscher får man räkna med att förutsättningarna kan ändras. Vissa marknader stängs ner och andra öppnas och regleras. Norge har idag inget lokalt licenssystem och istället för förbud hoppas jag att Norge rör sig mot en lokal reglering likt den utvecklingen vi ser i Sverige.", säger Gustaf Hagma
LeoVegas comments on information regarding the potential for changing circumstances in the Norwegian market25.4.2018 14:32 | Pressmeddelande
In LeoVegas financial targets of at least EUR 600 million in revenue in 2020 and at least EUR 100 million in EBITDA in 2020, that were presented on April 19th, it has been taken into account that market conditions can change. The announcement yesterday about the proposal in the Norwegian Parliament is an example of changing conditions that LeoVegas' strategic planning has made room for. LeoVegas strives to be a transparent company and therefore chooses to disclose the size of the Norwegian market in order to increase understanding of the potential impact. In March 2018, the Norwegian market accounted for 4.6% of LeoVegas total revenues. Regardless of the outcome the development in Norway, it does not affect LeoVegas financial targets. "There are still no details about the proposal, but in all industries, one can expect that the conditions can change. Some markets are closed and others are opened and regulated. Norway currently has no local licensing system, and instead of prohibition,
Gemini to Launch Market Surveillance Technology in Collaboration with Nasdaq25.4.2018 12:30 | Pressmeddelande
Nasdaq is providing SMARTS Market Surveillance technology to monitor cryptocurrency market NEW YORK and STOCKHOLM, Sweden, April 25, 2018 (GLOBE NEWSWIRE) -- Gemini Trust Company, LLC (Gemini) and Nasdaq Inc. (Nasdaq:NDAQ) announced today that Gemini will be leveraging Nasdaq's SMARTS Market Surveillance technology to monitor its marketplace. The technology, which is considered the most widely deployed surveillance system in the world, will enable Gemini to monitor across all of its trading pairs, including: BTC/USD, ETH/USD and BTC/ETH. Further, SMARTS will also surveil activity across the Gemini auction process that is used to determine the settlement price for the Bitcoin XBT futures contracts that trade on Cboe's CFE Exchange. "Since launch, Gemini has aggressively pursued comprehensive compliance and surveillance programs, which we believe betters our exchange and the cryptocurrency industry as a whole," said Tyler Winklevoss, CEO, Gemini. "Our deployment of Nasdaq's SMARTS Market
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum